InnoLAMP TECHNOLOGY
G2GBIO developed a proprietary technology named InnoLAMP (Innovative Long-Acting Microsphere Platform) that overcomes the limitations of conventional manufacturing methods. Using InnoLAMP, G2GBio succeeded in producing competitive microspheres.
InnoLAMP (Innovative Long-Acting Microsphere Platform)
Principle of Drug Sustainability

Technology for uniform microsphere manufacturing & mass production
-
Particle size control

- Primary determination based on the pore size of the membrane
-
GMP-compliant High Scale-up

- Easy scale-up to manufacture up to several kilograms per hour
- Technology for uniform microsphere manufacturing & mass production

-
Pilot Manufacturing facility
capable of producing 10-30 kg of pharmaceuticals


and enables speedy production of highly soluble drugs such as peptides.
InnoLAMP (Innovative Long-Acting Microsphere Platform)
- Property
- G2GBIO's technology involves the production of uniform microspheres (10~100μm) by encapsulating drugs with biodegradable polymers
- Effect
- The drug is sustainably released over a period of one week to several months, allowing for long-lasting effects of the drug.
- Strength of InnoLAMP
-
- Precise size & release control
- The uniform production of microspheres and precise control over their release profile
- Easy Scale-Up
- Easier scale-up and sterile GMP production compared to the conventional technologies
- Diverse Applications
- Application in various diseases with unmet medical needs in terms of drug sustainability and medication adherence

InteLAMP TECHNOLOGY
It facilitates not only sustained release of drugs from microspheres but also uniform distribution of microspheres within the tumor tissue to selectively kill cancer cells
InteLAMP (Intelligent Local-Acting Microsphere Platform) Principle and Technology Differentiation
- Customized sustained-release microsphere treatments can be developed using InteLAMP technology

- Improved distribution of microspheres within tumors

[References]
1. Nature Reviews Clinical Oncology / Intratumoural administration and tumour tissue targeting of cancer immunotherapies / Ignacio Melero, Eduardo Castanon, Maite Alvarez, Stephane Champiat & Aurelien Marabelle / Published: 18 May 2021